Outcome of Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients

Sponsor

Uppsala University (Other)

Overall Status

Unknown status

CT.gov ID

NCT01623700

Collaborator

AstraZeneca (Industry)

78,000

Enrollment

Location

Study Details

Study Description

Brief Summary

This observational study will based on the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) and the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) which since 2009 are merged into The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART).

The aim of this study is to investigate the impact of different antithrombotic treatment options (treatment duration, type of treatment and combination of treatments) in Acute Coronary Syndrome (ACS) patients on outcomes such as recurrent ischemic events and mortality.

Condition or Disease	Intervention/Treatment	Phase
Acute Coronary Syndrome Myocardial Infarction

Study Design

Study Type:

Observational

Actual Enrollment :

78000 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients

Study Start Date :

Jan 1, 2006

Arms and Interventions

Arm	Intervention/Treatment
dual antiplatelet treatment 12 months after ACS event
dual antiplatelet treatment 6 months after ACS event
dual antiplatelet treatment 3 months after ACS event

Outcome Measures

Primary Outcome Measures

number of patients with adverse events in patient groups with different antithrombotic treatment strategies [up to 5 years and 6 months]
adverse events such as: mortality, re-infarction, revascularization, ischemic- and non-ischemic stroke and bleeding

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patient with an event of ACS under the study period
Patient found in the National Registry of Drug Prescriptions and treated or not treated with antithrombotic drug/s (acetylsalicylic acid and/or either clopidogrel/ticlopidine/prasugrel and/or warfarin)